About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation

Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease.

“The data at TCT on Edwards’ innovations underscore our commitment to scientific leadership and our focus to bring impactful and life-saving structural heart therapies to patients and physicians,” said Bernard Zovighian, Edwards’ CEO. “This new clinical evidence also advances Edwards’ opportunities within both TAVR and TMTT to treat more patients with our advanced technologies and support long-term, sustainable growth across the company in the years ahead.”

The data, including results from the groundbreaking EARLY TAVR and TRISCEND II trials, highlighted outcomes from studies that focused on previously understudied patient groups. The findings emphasized that timely treatment of structural heart disease not only enhances clinical outcomes and quality of life for patients, but also reduces long-term healthcare costs.

Transcatheter Aortic Valve Replacement (TAVR)

New data provided compelling evidence about TAVR, particularly for patients without symptoms but suffering from severe aortic stenosis, including:

  • A meta-analysis highlighting the importance of early intervention in asymptomatic severe aortic stenosis patients and reinforcing the results from the EARLY TAVR trial.
  • A pooled analysis of RHEIA + PARTNER 3 data highlighting the efficacy and safety of Edwards TAVR in women.
  • Insights into delays in care for aortic valve replacement (AVR), finding pre-procedural requirements contribute to TAVR patients waiting significantly longer than SAVR patients to access treatment.
  • An assessment of the value of timely treatment of aortic stenosis, finding that intervening at earlier stages of cardiac damage helps save costs and healthcare resources.

Transcatheter Mitral and Tricuspid Therapies (TMTT)

Additionally, new evidence was presented on Edwards’ portfolio of transcatheter mitral and tricuspid repair and replacement therapies, reinforcing the strength of the company’s innovations beyond TAVR, including:

  • The two-year outcomes from the pivotal CLASP IID trial, showcasing sustained benefits of PASCAL in treating degenerative mitral regurgitation in a broad patient population.
  • An analysis of the healthcare resource utilization and costs associated with tricuspid regurgitation, highlighting the economic impact of timely intervention.
  • One-year results from the TWIST global feasibility study, demonstrating promising outcomes for Innovalve in transcatheter mitral valve replacement, which was recently acquired by Edwards.
  • Data from the PASTE registry, encompassing more than 1,000 European patients treated with PASCAL in the tricuspid position, underscoring its safety and effectiveness.

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by Mr. Zovighian and statements regarding expected product benefits, including safety and efficacy, other benefits including costs and health care resources, patient outcomes, objectives and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.

Edwards, Edwards Lifesciences, the stylized E logo, CLASP, CLASP II, EARLY TAVR, PARTNER, PASCAL, TRISCEND, and TRISCEND II are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

Contacts

Media Contact: Amy Hytowitz, 949-250-4009

Investor Contact: Mark Wilterding, 949-250-6826

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.58
+6.10 (2.82%)
AAPL  263.38
+1.14 (0.44%)
AMD  238.80
-1.76 (-0.73%)
BAC  51.63
-0.41 (-0.78%)
GOOG  252.49
-4.53 (-1.76%)
META  732.29
+0.12 (0.02%)
MSFT  516.22
-0.57 (-0.11%)
NVDA  181.28
-1.36 (-0.75%)
ORCL  275.84
-1.34 (-0.48%)
TSLA  446.02
-1.41 (-0.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.